Readcrest Capital AG Sets EBITDA Guidance for 2026

Hamburg-based Readcrest Capital AG has forecasted its adjusted EBITDA for the 2026 financial year between EUR 8.0 million and EUR 9.0 million. This estimation accounts for a significant contribution from Grosvenor Health and Social Care, expected to generate around EUR 12 million, offset by German project development earnings, anticipated to subtract EUR 3-4 million.

The guidance follows the company's strategic focus shift post the UK care home business divestment. Grosvenor Health remains pivotal in revenue generation. Additionally, Readcrest emphasises expanding in real estate, specifically residential projects in Germany's high-growth areas, which are projected to drive future value and complement existing healthcare sector cash flows.

By the end of 2026, Readcrest targets an annualised EBITDA run-rate of EUR 11.0 million to EUR 12.0 million. Key projects include the upcoming Dresden construction and a sales launch in Halle, ensuring diversified growth.